Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar- bevacizumab) as 1L Therapy for Hepatocellular Carcinoma
Shots:
- The acceptance of sNDA is based on P-III ORIENT-32 study assessing in sintilimab + bevacizumab vs sorafenib in 571 subjects in a ratio (2:1) as 1L treatment for patients with advanced HCC
- The study met the pre-defined efficacy criteria which showed significant improvement in OS and PFS as assessed by IRRC
- This marks the fifth NDA application of Tyvyt that has been accepted for review by NMPA. Meanwhile- the application also seeks the fourth indication for Byvasda
Ref: Innovent Bio | Image: Innovent
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com